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Background: Tocopheryl acetate is viscous oily fluid used in a range of preparations for skin and scalp care in Italy.
Observational and in vitro data have suggested a high level of efficacy against head louse infestation. The purpose
of this investigation was to confirm the activity of tocopheryl acetate in a clinical setting in comparison with a
standard widely used preparation.
Methods: A spray formulation containing tocopheryl acetate 20% in cyclomethicone was compared with
permethrin 1% creme rinse for treatment of head louse infestation in a randomised, assessor blind, trial. Forty-five
people were treated on two occasions 7 days apart. The spray was applied to dry hair for 20 minutes then washed.
Participants treated with permethrin washed their hair and towel dried it before treatment for 10 minutes.
Assessments were made by dry detection combing 1, 6, 9, and 14 days after first treatment.
Results: The tocopheryl acetate 20% spray was significantly (p = 0.033) more effective than permethrin 1%, using
intention to treat worst case analysis, in which there were 13/23 (56.5%) successful treatments for tocopheryl
acetate compared with 5/22 (22.7%) for permethrin. After unprecedented issues of re-infestation within households
had been taken into account the underlying cure rate was 17/23 (73.9%) for tocopheryl acetate compared with
5/22 (22.7%), Odds Ratio 9.63 (95% CI, 2.46 to 37.68) (p < 0.001).
Conclusions: The tocopheryl acetate spray was significantly more effective than the permethrin product, was
cosmetically acceptable, and not affected by current problems with resistance.
Trial registration: Current Controlled Trials ISRCTN45553737.
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Tocopheryl acetate, a vitamin-E ester, has long been
used as a skin emollient and anti-oxidant in a variety
of cosmetic and cosmeceutical preparations. Tocopheryl
acetate has limited applications on its own because it is a
high viscosity (>700 centistokes (cSt)), high surface ten-
sion (0.0337 newtons/metre (N/m)) oil, and is there-
fore normally formulated in more fluid materials such
as decamethylcyclopentasiloxane, a low surface tension
(0.018 N/m), low viscosity (2.4 cSt) silicone solvent. This
type of mixture is capable of delivering small quantities of* Correspondence: ian@insectresearch.com
Medical Entomology Centre, Insect Research & Development Limited,
Cambridge, UK
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reproduction in any medium, provided the orthe active substance to target sites that would otherwise be
inaccessible to the viscous fluid.
Fluid medical devices based on synthetic oils are widely
used in Europe, Australia, and South America to control
head lice and are generally claimed to block the respiratory
structures of the insects [1-4]. However, increasing num-
bers of consumers express an interest to use naturally de-
rived materials rather than mineral oils. Relatively few
fixed plant oils have been shown to have activity and some
are relatively unstable or have only been tested in devel-
oping countries [5,6], which may explain why, in several
European countries, the use of neurotoxic insecticides
against head lice persists despite evidence that many of the
products are no longer effective.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a variety of protective or preventive barrier applications
on inflamed or dry skin and in the spray dosage form
was also designed to be suitable for application to the
hair and scalp as a general conditioning agent. This use
was incidentally seen to have novel potential as an anti-
head louse agent. As a preliminary to investigating clin-
ical control of head lice using the 20% tocopheryl acetate
spray, we ran a series of ex vivo tests against head lice,
which confirmed that 20% tocopheryl acetate completely
immobilises lice and inhibits the hatching of louse eggs
in a similar way to dimeticone based products [7]. As a
result a class I medical device based on this activity was
registered in Italy in 2010.
Here we report a clinical investigation conducted using
the methodologies underpinning the recently published
guidelines for trials of pediculicides [8]. The study com-
pared a patented tocopheryl acetate 20% spray with an
insecticide product based on 1% permethrin, the most
potent of the pyrethroid insecticides used against lice.
Methods
Objective and participants
Participants were recruited to the study in essentially the
same way as used for previous trials by advertising on local
radio and by direct contact with previous study partici-
pants who had expressed an interest in taking part in fur-
ther research. Potential participants were supplied with an
information booklet prior to recruitment, and an enrol-
ment visit arranged a minimum of 24 hours later.
We screened all assenting members of each household
for presence of live lice by using a plastic detection comb
(“PDC” comb, KSL Consulting, Helsinge, Denmark) on dry
hair. Each infested member could be enrolled if: older than
6 months; had not been treated with head louse products
during the previous 2 weeks; or treated with trimethoprim
containing products during the previous 4 weeks. We also
excluded those who had used permanent waves or hair col-
ours during the previous 4 weeks because some products
in these categories still use thiol-based ingredients that
may exert an insecticidal effect, particularly against louse
eggs, and some prospective participants had used them for
this purpose in the past. We asked all prospective partici-
pants to confirm that they were unaware of allergy or sen-
sitivity to pyrethroid insecticides or any other ingredient of
the test products. Adult females also confirmed they were
not breast feeding or pregnant, and using adequate contra-
ception. We excluded people with long-term scalp condi-
tions other than head louse infestation, earlier participants
in this trial, and anyone who had participated in another
clinical study within 1 month before screening.
At the first visit we also collected baseline demographic
data on gender, age, hair characteristics, and previous
pediculicide use. All treatments and assessment visitswere domiciliary and no payment was offered for par-
ticipation. Any ineligible people infested with lice were
offered a standard of care treatment (4% dimeticone li-
quid gel) to minimise the risk of reinfestation of study
participants.
Ethics
Ethical approval for the study was granted by NRES
Committee South Central - Berkshire B (EudraCT 2011-
001892-38).
The study was conducted in conformity with the prin-
ciples of the Declaration of Helsinki, of European Union
Directive 2001/20/EC, and of the ICH Topic E11 guide-
line. All participants stated before giving consent that
they had read the participation information booklet (PIB)
and understood the purpose and requirements of the
study. Parents or guardians gave written consent for chil-
dren younger than 16 years. Children also provided writ-
ten or verbal assent, according to age, witnessed by the
parent or guardian.
Treatment
The products were different both physically and in the
method of application, so this study was single blinded
with post-treatment assessments performed by investiga-
tors unaware of which treatment products had been used
(assessor blinded). The products were applied following
the instructions for use given by the manufacturers.
Tocopheryl acetate 20% spray (LiceKO®, Panin S.r.l,
Rovigo, Italy) is made from allergen free, nature identical,
tocopheryl acetate dissolved in decamethylcyclopenta-
siloxane (cyclomethicone) in a 20:80 ratio [7]. It was sup-
plied in 100 mL bag-in-can sprays, i.e. the pressurised air
propellant gas is not mixed with the product so pH stabil-
isation is not an issue. We applied the spray directly to dry
hair, massaging it in with fingers, working systematically
around the scalp to ensure even coverage. The treatment
time was 20 minutes followed by washing with shampoo
and rinsing out.
Permethrin 1% creme rinse (Lyclear® creme rinse, Omega
Pharma UK, London, UK) is made from 1% 25:75 cis:trans
permethrin in a conditioning base containing 20% propan-
2-ol as a co-solvent. It was supplied in 59 mL plastic
bottles with a flip cap dispenser. It was applied after wash-
ing the hair with a non-medicated shampoo followed by
towel drying. We applied the rinse a few millilitres at a
time and massaged in to thoroughly coat the hair and
scalp. It was left in place for 10 minutes followed by rinsing
out with water. Parents/care givers performed the hair
washing and rinsing.
The first treatment day was designated Day 0. We re-
peated the treatments 7 days later. We asked participants
not to use nit combs or other louse treatments during the
course of the study.
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The primary outcome measure for the study was elimin-
ation of lice after two applications of product. We assessed
efficacy by dry detection combing on Days 1 and 6, before
the second treatment, then on Days 9 and 14. Any lice
found were collected, fixed into the case record, and exam-
ined by microscope to determine the development stage. A
successful treatment was defined as no lice found on Days
9 and 14.
Outcomes of treatment were classified as cure, reinfes-
tation following cure, or treatment failure.
Sample size
We designed the study so we could detect superior ac-
tivity of either product. We assumed that all participants
were independent. Although there is ample evidence of
widespread resistance to permethrin it is still used as a
benchmark for comparison with novel treatments. Con-
sequently, we expected a considerable difference in out-
come between the two treatments and, using previously
reported outcomes for permethrin [9-11], we estimated
a success rate of about 30%. Ex vivo data for tocopheryl
acetate indicated a potential for complete success [7],
but such outcomes are rarely encountered in practice so
our estimate for clinical success was likely to be of the
order of 90%.
We estimated a sample size of 44 participants (22 per
group) had more than 95% confidence and 90% power
to detect a difference in the success rates of 60% be-
tween the two products, following the second treatment.
The sample size made allowance for dropout. This sam-
ple size was also able to detect a difference of 42% with
90% confidence and 80% power.
Randomisation and blinding
The randomised treatment allocation sequence was de-
rived using an online computer generated list from http://
www.randomization.com (seed 10028, 23rd September
2011). We used instruction sheets enclosed in opaque,
sealed, sequentially numbered envelopes, distributed to in-
vestigators in balanced blocks of 8, to hide the allocation
until the point of delivery. A copy of the listing was pre-
pared in case an emergency code break was required. In-
vestigators allocated the numbered envelopes in sequence.
Randomisation was by individual so different family mem-
bers could receive different treatments.
Statistics and outcome measures
Statistical analyses were performed blind of treatment
allocation. Fisher exact tests were used for presence/
absence variables. Differences in success rates were mea-
sured by the 95% confidence interval calculated using
a normal approximation to the binomial distribution.
Quantitative variables were compared by using the Mann–Whitney U test. We conducted analyses using Oxstat II,
version 1.1, EpiInfo, version 6, and purpose built calcula-




We performed this study in Cambridgeshire, UK. Be-
tween 10th October 2011 and 2nd February 2012, we
screened 75 people for head lice and enrolled 45 partici-
pants in the study from 28 households. A further 60
household members either declined screening, were in-
eligible, or were unavailable. Enrolled people comprised
39 children and 6 adults aged between 2 and 45 years,
median 9 years. Demographic characters of this study
population showed no significant differences from popu-
lations enrolled in recent previous studies [9-12]. The
proportion of participants with heavier infestations at
enrolment was also similar to previous studies.
We enrolled 10 households with more than one par-
ticipating family member: 7 families having two, and one
family each for three, four, and six participants. The
most common household sizes were five (8 houses), four
(7 houses), three and six (6 houses) each. We planned
for equal numbers of people receiving each treatment
(22 per group) with a final enrolment of 23 receiving
tocopheryl acetate 20% spray and 22 receiving permeth-
rin 1% creme rinse. All 45 participants completed all
study assessments and there were no instances of non-
compliance. Consequently, all participants were included
in both the intention to treat (ITT) and per-protocol
(PP) analyses (Figure 1).
The main endpoint analysis was the comparison of
rate of cure in the 45 participants in the ITT population.
According to this criterion, using worst case analysis,
tocopheryl acetate 20% spray performed significantly better
(p = 0.033, 95% confidence interval (CI), 0.05 to 0.62) with
success achieved for 13/23 (56.5%) of the participants com-
pared with 5/22 (22.7%) of those treated with permethrin
1% creme rinse, a difference of 33.8% (Odds Ratio (OR)
4.42, 95% CI, 1.21 to 16.12).
The reason we performed a worst case analysis is be-
cause randomisation in this study produced an unusually
high proportion of households in which at least two
members received different treatments. The result was
that tocopheryl acetate eliminated lice from several people
who were then reinfested from family members receiving
the much less effective permethrin. When we analysed the
lice collected during post-treatment assessments it indi-
cated a higher actual treatment success rate for tocopheryl
acetate of 17/23 (73.9%), without a similar change in the
outcome for permethrin, a difference of 51.2% (OR 9.63,
95% CI, 2.46 to 37.68). This analysis also revealed that the
20% tocopheryl acetate spray was not able to prevent all
Screened (n =75) 
Not randomized (n = 30) 
Reasons:
No lice (n = 30)
Randomized (n= 45)
Allocated tocopheryl acetate  
spray (n = 23) 
Allocated permethrin creme  
rinse (n = 22) 
Protocol violations: (n = 0)
Analyzed ITT (n = 23)
Protocol violations: (n = 0)
Analyzed Per protocol (n = 23) 
Analyzed ITT (n = 22)
Analyzed Per protocol (n = 22) 
Not screened (n = 60)
Reasons:
Declined, ineligible, or unavailable
Figure 1 Flowchart of participants enrolled in the study.
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emerged nymphs were found on 14 participants between
the first and second treatments. Six participants (26.1%)
also had newly emerged nymphs following the second ap-
plication of spray, showing that some eggs may take longer
than 7 days to hatch.
Although we found lice in both groups before the sec-
ond treatment on Day 7, applying the spray a second
time eliminated the majority of infestation. After the sec-
ond treatment, people in the tocopheryl acetate 20%
group had significantly (p < 0.05) fewer lice of any devel-
opment stage except adult females at Day 9, and adults
and third stage nymphs at Day 14. These adult lice and
older nymphs, which had migrated from infested family
members treated with permethrin, reduced the overall
efficacy outcome for tocopheryl acetate from 73.9% to
56.5%. We also analysed the distribution of outcome and
success rates for subsets of the population by various
factors: sex, age, level of initial infestation, hair length,
hair thickness, hair curl, and hair type. Additional tests
were made for the significance of variations in the ratesof cure or re-infestation by levels of these factors and
the results are summarised in Table 1.
Given the small sample size, it was not surprising that
few differences or trends were significant at p < 0.05. How-
ever, we did find significant trend differences (p < 0.05) be-
tween the treatment groups for females, and those with a
“light” infestation at enrolment, and in the populations
overall. The most highly significant difference of outcome
was in those with “wavy” hair (p < 0.01), possibly due to
the quantity of preparation that could be held by the hair,
which would have influenced the level of contact between
the product and the lice and louse eggs. Nearly all (20/23)
people treated with tocopheryl acetate and their carers
expressed a preference for using the spray compared with
the permethrin creme rinse with respect to comfort and
convenience, as well as success of outcome.
We weighed the containers of product before and after
use to measure product usage. Slightly more treatment
was applied on the first occasion than the second, with a
mean application of 39.5 g of spray. In contrast the
mean quantity of creme rinse used was nearly double for
Table 1 Rates of cure overall and by data subgroup - ITT population
Success rate p value
Tocopheryl acetate 20% Permethrin 1%
n/N % n/N %
Whole population
Elimination of initial infestation 17/23 73.9 5/22 22.7 <0.001
Worst case analysis 13/23 56.5 5/22 22.7 0.033
Data subgroup
Sex - males 1/2 50.0 1/3 33.3 NS
- females 12/21 57.1 4/19 21.1 0.027
Age - 2 to 9 10/13 76.9 4/11 36.4 NS
- 10 to 15 1/7 14.3 0/8 0.0 NS
- 16+ 2/4 50.0 1/3 33.3 NS
Infestation - light 9/12 75.0 3/11 27.3 0.039
- moderate 2/4 50.0 2/5 40.0 NS
- heavy 2/7 28.6 0/5 0.0 NS
Hair length - above ears 1/2 50.0 1/3 33.3 NS
- ears to shoulders 5/9 55.6 1/7 14.3 NS
- below shoulders 7/12 58.3 3/12 25.0 NS
Hair thickness - fine 3/4 75.0 2/4 50.0 NS
- medium 4/6 66.7 1/6 16.7 NS
- thick 6/13 46.2 2/12 16.7 NS
Hair curl - straight 4/11 36.4 4/14 28.6 NS
- wavy 6/8 75.0 0/6 0.0 <0.01
- curly 3/4 75.0 1/2 50.0 NS
Hair type - dry 1/2 50.0 1/2 50.0 NS
- normal 11/19 57.9 5/18 27.8 NS
- greasy 1/2 50.0 0/2 0.0 NS
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treatment application proved to be similar for each
product at approximately €6.50 to €6.85.
Adverse events
There were 13 adverse events in 13 participants, of which
11 were simple accidents or childhood infections not re-
lated to treatment. One adverse event in each group was an
application site event of stinging or itching considered to
have some relationship to treatment or the washing process
involved in removing the treatment. In the case of per-
methrin creme rinse, stinging occurred during the treat-
ment application process, indicating irritation of existing
excoriations by the treatment. In the case of tocopheryl
acetate spray, itching occurred during the washing off pro-
cess that was possibly associated with the shampoo used.
Discussion
We have found that tocopheryl acetate, applied as a 20%
spray, was significantly more effective to eliminate headlice than the insecticide permethrin. We have also found
evidence that resistance to pyrethroid insecticides like
permethrin has not diminished in the study area despite
reduced use of the insecticide during the past few years.
However, the presentation of resistance in the UK is
largely different from that in some other countries where
susceptibility to pyrethroids may be reduced, but not elimi-
nated, and resistance to alternative insecticides like mala-
thion is either not found or is of limited impact [13,14].
Although knockdown resistance (kdr) is present in the
country it appears to play only a minor role in treatment
failure compared with a double resistance to permethrin
and malathion mediated by elevated levels of non-specific
esterases [Burgess IF, unpublished] [15]. As a result, the
impact of resistance has continued to reduce efficacy of in-
secticide based products to the point that they are now ef-
fectively useless for many consumers [9-12,16].
The mode of action of tocopheryl acetate to kill head
lice is currently unconfirmed but, as it is hydrophobic
and has a high viscosity (>700 cSt), we believe it has an
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acular structures in a similar manner to the high mo-
lecular weight dimeticone used in some of the most
widely used products in Europe [3].
Since 2005, physically acting medical device products for
control of head louse infestation have increased in number,
availability, and variety of dosage form and have largely re-
placed insecticides in several countries in Europe, and have
a large market share in Australia and New Zealand. How-
ever, clinical data are only available in the public domain
for a limited number of these products. This treatment
concept is generally popular with consumers because the
products do not contain insecticides and most do not con-
tain irritating solvents or preservatives. But comments
from consumers indicate that some are not effective and
others are difficult to use.
In recent times an additional problem for all families
attempting to eliminate head louse infestation has been
reinfestation. Irrespective of the effectiveness of the prod-
uct they are using there is no protection after washing
the treatment off so the children could potentially be
reinfested from the next contact with their friends. Fortu-
nately in most households everyone is normally treated
using the same product so that everyone is usually ei-
ther cured or not at the same time. In clinical studies
randomised by individual it is often the case that some
households have different members receiving different
treatments. For most medications this does not constitute
an issue but for head louse studies, if there is a disparity of
efficacy, those receiving the more effective product are at
continual risk of reinfestation from those on the less effect-
ive one. This is an issue we have addressed in the past by
development of an algorithm to identify where the few
cases of reinfestation occur [9-12,16]. However, in this
study a high proportion of households had people in re-
ceipt of different treatments, and most people receiving
permethrin still had lice after treatment. As a result it was
inevitable that any siblings who had been treated with
tocopheryl acetate would be at risk of reinfestation, which
was identified by being found to be free from lice after
treatment but infested again by adult lice and third stage
nymphs by the end of the study. Of course, it is impossible
to confirm absolutely that the reinfestation arose from such
contacts, which is why we conducted a worst case analysis
also. Perhaps for this reason it would be wiser to consider
randomisation by household in future studies but this has
drawbacks because it requires larger numbers of partici-
pants, which could make the cost of investigations prohibi-
tive for small companies, and has hitherto not been
favoured by some regulatory agencies who have preferred
randomisation by individual because each person is seen as
being independent [12].
Fixed vegetable oils, such as olive and coconut oils, have
been used as hair grooming agents for centuries in severalcultures while others such as neem have been used to
treat infections and infestations. Whether they have any
real activity against head lice is unknown but modern
folklore from the USA, and other western cultures where
these oils are not routinely used, suggests they occlude
the louse respiratory tract, similar to the activity of syn-
thetic oils. However, with a low viscosity of the order of
80–90 cSt combined with a low surface tension, these
oils would form a thin film on lice and hairs that could
only act slowly and may not deliver sufficient material to
the respiratory structures of the lice. Certainly, in geo-
graphic areas where these vegetable oils are routinely
used on hair, lice are common and appear to survive un-
hindered by the oils. Neem seed oil, which is marketed
as a shampoo formulated material, is reported to demon-
strate a rapid activity, killing lice within a few minutes
[5,6]. Such speed of effect is unlikely to occur by occlu-
sion alone because neem oil is chemically similar to extra
virgin olive oil but with the addition of small quantities
of a number of complex terpenoids. The reported rapid
activity of neem shampoo either suggests a pharmaco-
logical activity, which would place the preparations into
the sphere of medicinal products rather than devices, or
else the activity must be due to formulation components
other than neem such as powerful surfactants stripping the
lipid from the louse surface. Similarly, eucalyptus and tea
tree oils, as well as other monoterpene based products,
are reported to show good efficacy [4,9,17-19] but these
oils have a recognised activity to inhibit acetylcholine
esterase and other enzymes [20], which would make them
pharmacologically active also.
Tocopheryl acetate is different from other products
based on natural materials because it has a high viscosity
causing it to adhere to lice or hair without absorption
across the insect cuticle. As a 20% spray in a low viscos-
ity carrier, tocopheryl acetate becomes an effective phys-
ical occlusive agent that is not easily removed from the
hydrophobic louse cuticle by shampoo. Consequently,
even a short application time of 20 minutes proved ef-
fective because the immobilised lice remain coated with
the active material. As a preparation we have found it
to be of similar efficacy to other widely accepted phys-
ically acting preparations but with the added appeal
for consumers that it is “naturally” based. Like the ori-
ginal cosmetic tocopheryl acetate spray upon which this
product was based (Vea® Spray, Hulka S.r.l., Rovigo,
Italy), it has the added effect to reduce inflammation of
the scalp resulting from previous louse bites, thus redu-
cing irritation and dryness. Future investigations will
look at ways to limit flow of the sprayed fluid along the
hair shafts, which should reduce the quantity of prod-
uct required for an adequate treatment and improve
the performance of the product overall, particularly against
louse eggs.
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In this randomized, controlled, assessor-blinded, clinical
investigation we have shown that a 20% tocopheryl acetate
based spray (LiceKO® spray) was significantly more effect-
ive than a 1% permethrin creme rinse. The product was
both better tolerated and more cosmetically acceptable.
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